Cargando…
Immune Phenotypic Characterization of a TRAIL-Knockout Mouse
SIMPLE SUMMARY: The role of the TNF-superfamily member TRAIL (TNF-related apoptosis inducing ligand) for potential interactions with the immunological tumor network is not completely understood. This article provides a comprehensive immune phenotype profile of a TRAIL-knockout (TRAIL(−/−)) mouse mod...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000729/ https://www.ncbi.nlm.nih.gov/pubmed/36900266 http://dx.doi.org/10.3390/cancers15051475 |
_version_ | 1784903951440674816 |
---|---|
author | Stoyanova, Ani K. Sattler, Arne Hahn, Elisabeth M. Hering, Nina A. Arndt, Marco Lauscher, Johannes Christian Speichinger-Hillenberg, Fiona Kotsch, Katja Berg, Ann-Kathrin Beyer, Katharina |
author_facet | Stoyanova, Ani K. Sattler, Arne Hahn, Elisabeth M. Hering, Nina A. Arndt, Marco Lauscher, Johannes Christian Speichinger-Hillenberg, Fiona Kotsch, Katja Berg, Ann-Kathrin Beyer, Katharina |
author_sort | Stoyanova, Ani K. |
collection | PubMed |
description | SIMPLE SUMMARY: The role of the TNF-superfamily member TRAIL (TNF-related apoptosis inducing ligand) for potential interactions with the immunological tumor network is not completely understood. This article provides a comprehensive immune phenotype profile of a TRAIL-knockout (TRAIL(−/−)) mouse model and should serve as a tool to study the functional relevance of TRAIL in proof-of-concept studies. ABSTRACT: The TNF-superfamily member TRAIL is known to mediate selective apoptosis in tumor cells suggesting this protein as a potential antitumor drug target. However, initial successful pr-clinical results could not be translated into the clinic. Reasons for the ineffectiveness of TRAIL-targeting in tumor therapies could include acquired TRAIL resistance. A tumor cell acquires TRAIL resistance, for example, by upregulation of antiapoptotic proteins. In addition, TRAIL can also influence the immune system and thus, tumor growth. We were able to show in our previous work that TRAIL(−/−) mice show improved survival in a mouse model of pancreatic carcinoma. Therefore, in this study we aimed to immunologically characterize the TRAIL(−/−) mice. We observed no significant differences in the distribution of CD3(+), CD4(+), CD8(+) T-cells, Tregs, and central memory CD4(+) and CD8(+) cells. However, we provide evidence for relevant differences in the distribution of effector memory T-cells and CD8(+)CD122(+) cells but also in dendritic cells. Our findings suggest that T-lymphocytes of TRAIL(−/−) mice proliferate at a lower rate, and that the administration of recombinant TRAIL significantly increases their proliferation, while regulatory T-cells (Tregs) from TRAIL(−/−) mice are less suppressive. Regarding the dendritic cells, we found more type-2 conventional dendritic cells (DC2s) in the TRAIL(−/−) mice. For the first time (to the best of our knowledge), we provide a comprehensive characterization of the immunological landscape of TRAIL-deficient mice. This will establish an experimental basis for future investigations of TRAIL-mediated immunology. |
format | Online Article Text |
id | pubmed-10000729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100007292023-03-11 Immune Phenotypic Characterization of a TRAIL-Knockout Mouse Stoyanova, Ani K. Sattler, Arne Hahn, Elisabeth M. Hering, Nina A. Arndt, Marco Lauscher, Johannes Christian Speichinger-Hillenberg, Fiona Kotsch, Katja Berg, Ann-Kathrin Beyer, Katharina Cancers (Basel) Article SIMPLE SUMMARY: The role of the TNF-superfamily member TRAIL (TNF-related apoptosis inducing ligand) for potential interactions with the immunological tumor network is not completely understood. This article provides a comprehensive immune phenotype profile of a TRAIL-knockout (TRAIL(−/−)) mouse model and should serve as a tool to study the functional relevance of TRAIL in proof-of-concept studies. ABSTRACT: The TNF-superfamily member TRAIL is known to mediate selective apoptosis in tumor cells suggesting this protein as a potential antitumor drug target. However, initial successful pr-clinical results could not be translated into the clinic. Reasons for the ineffectiveness of TRAIL-targeting in tumor therapies could include acquired TRAIL resistance. A tumor cell acquires TRAIL resistance, for example, by upregulation of antiapoptotic proteins. In addition, TRAIL can also influence the immune system and thus, tumor growth. We were able to show in our previous work that TRAIL(−/−) mice show improved survival in a mouse model of pancreatic carcinoma. Therefore, in this study we aimed to immunologically characterize the TRAIL(−/−) mice. We observed no significant differences in the distribution of CD3(+), CD4(+), CD8(+) T-cells, Tregs, and central memory CD4(+) and CD8(+) cells. However, we provide evidence for relevant differences in the distribution of effector memory T-cells and CD8(+)CD122(+) cells but also in dendritic cells. Our findings suggest that T-lymphocytes of TRAIL(−/−) mice proliferate at a lower rate, and that the administration of recombinant TRAIL significantly increases their proliferation, while regulatory T-cells (Tregs) from TRAIL(−/−) mice are less suppressive. Regarding the dendritic cells, we found more type-2 conventional dendritic cells (DC2s) in the TRAIL(−/−) mice. For the first time (to the best of our knowledge), we provide a comprehensive characterization of the immunological landscape of TRAIL-deficient mice. This will establish an experimental basis for future investigations of TRAIL-mediated immunology. MDPI 2023-02-25 /pmc/articles/PMC10000729/ /pubmed/36900266 http://dx.doi.org/10.3390/cancers15051475 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stoyanova, Ani K. Sattler, Arne Hahn, Elisabeth M. Hering, Nina A. Arndt, Marco Lauscher, Johannes Christian Speichinger-Hillenberg, Fiona Kotsch, Katja Berg, Ann-Kathrin Beyer, Katharina Immune Phenotypic Characterization of a TRAIL-Knockout Mouse |
title | Immune Phenotypic Characterization of a TRAIL-Knockout Mouse |
title_full | Immune Phenotypic Characterization of a TRAIL-Knockout Mouse |
title_fullStr | Immune Phenotypic Characterization of a TRAIL-Knockout Mouse |
title_full_unstemmed | Immune Phenotypic Characterization of a TRAIL-Knockout Mouse |
title_short | Immune Phenotypic Characterization of a TRAIL-Knockout Mouse |
title_sort | immune phenotypic characterization of a trail-knockout mouse |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000729/ https://www.ncbi.nlm.nih.gov/pubmed/36900266 http://dx.doi.org/10.3390/cancers15051475 |
work_keys_str_mv | AT stoyanovaanik immunephenotypiccharacterizationofatrailknockoutmouse AT sattlerarne immunephenotypiccharacterizationofatrailknockoutmouse AT hahnelisabethm immunephenotypiccharacterizationofatrailknockoutmouse AT heringninaa immunephenotypiccharacterizationofatrailknockoutmouse AT arndtmarco immunephenotypiccharacterizationofatrailknockoutmouse AT lauscherjohanneschristian immunephenotypiccharacterizationofatrailknockoutmouse AT speichingerhillenbergfiona immunephenotypiccharacterizationofatrailknockoutmouse AT kotschkatja immunephenotypiccharacterizationofatrailknockoutmouse AT bergannkathrin immunephenotypiccharacterizationofatrailknockoutmouse AT beyerkatharina immunephenotypiccharacterizationofatrailknockoutmouse |